UK shareholder meetings calendar - next 7 days
22nd Dec 2023 15:50
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
SkinBioTherapeutics PLC - Newcastle, England-based life science company focused on skin health - Raises GBP3.0 million through placing of 15.9 million shares at 19 pence each. Says placing was completed through an accelerated bookbuild and was "materially oversubscribed". Placing price represents a 9.5% discount to SkinBio's closing middle market price of 21p per share on November 15, the day before it launched the placing. Company says the placing shares will be admitted to AIM on Wednesday and will represent around 9.2% of its total issued share capital. Read More
(Alliance News) - (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - OptiBiotix Health PLC on Wednesday said sales from existing partners have improved in recent months, and that its move to focus on US and Asian markets is progressing well. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
SkinBioTherapeutics PLC - Newcastle-based life science company focused on skin health - Extends its collaboration contract with Sederma SAS, the cosmetics arm of Croda International PLC, for another 12 months. Says the extension is so Sederma can complete and assess further studies on SkinBiotix technology to look at "previously unseen beneficial properties", which could "significantly enhance commercial opportunities". Sederma will cover any costs of SkinBioTherapeutics concerning the supply of SkinBiotix for the studies."We are confident that this can lead to a wider commercialisation of our SkinbiotixTM technology into new products, which can make a great difference to consumers with a wide array of skincare needs," says CEO Stuart Ashman. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More
(Alliance News) - SkinBioTherapeutics PLC on Friday said it has received approval from regulators to sell AxisBiotix-Ps, a food supplement designed to treat symptoms of psoriasis, to consumers in France. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
SkinBioTherapeutics PLC - Newcastle-based life science company focused on skin health - Receives regulatory approval to issue AxisBiotix-Ps in Italy. This follows the launch of AxisBiotix-Ps in Spain, after having received approval in March. Says the next target country for launch of the product is France, with talks with French regulators already underway. AxisBiotix-Ps is a food supplement used to alleviate Psoriasis symptoms. Read More
SkinBioTherapeutics PLC - life science company focused on skin health - Notes share price slide but says "not aware of any rationale for the movement". Read More
(Alliance News) - SkinBioTherapeutics PLC on Wednesday said that a partner has plans to undertake additional studies on SkinBiotix, which could enhance its commercial potential. Read More
SkinBioTherapeutics PLC - skin health-focused life sciences firm - Says interim revenue jumps to GBP76,985 in the six months to December 31, from GBP21,949 a year before. Pretax loss widens to GBP1.4 million from GBP1.2 million, as operational costs climb to GBP918,103 from GBP764,750. In 2023, says focus is on reaching commercial traction with Croda, launching AxisBiotix-Ps into Europe, developing an acne product, among others targets. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More
(Alliance News) - SkinBioTherapeutics PLC on Tuesday said it received Spanish health authority authorisation for AxisBioTix-Ps, its food supplement to treat symptoms associated with psoriasis. Read More